Loomis, Sayles & Company
MRVI icon

Loomis, Sayles & Company’s Maravai LifeSciences MRVI Stock Holding History

Loomis, Sayles & Company’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-661
Closed -$4K – 872
2023
Q4 		$4K Sell
661
-89
-12% -$575 ﹤0.01% 910
2023
Q3 		$8K Buy
750
+396
+112% +$4.35K ﹤0.01% 843
2023
Q2 		$4K Sell
354
-1,266
-78% -$17.1K ﹤0.01% 888
2023
Q1 		$23K Buy
+1,620
New +$23.3K ﹤0.01% 720
2022
Q4 		– Sell
-79
Closed -$2K – 941
2022
Q3 		$2K Hold
79
– – ﹤0.01% 822
2022
Q2 		$2K Hold
79
– – ﹤0.01% 858
2022
Q1 		$3K Buy
+79
New +$2.65K ﹤0.01% 881
2021
Q4 		– Sell
-231
Closed -$11K – 857
2021
Q3 		$11K Buy
+231
New +$11.3K ﹤0.01% 789

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company's MRVI Position: Q1 2024 in Review

Loomis, Sayles & Company sold out of Maravai LifeSciences (MRVI) in Q1 2024, closing a stake of 661 shares — an estimated $4K sold.

Loomis, Sayles & Company first reported a position in MRVI in Q3 2021 and held it in 8 quarters. The position peaked at $23K in Q1 2023. 210 funds tracked by Wall St. Rank hold MRVI as of Q1 2024.

  • Loomis, Sayles & Company reported no remaining Maravai LifeSciences position as of Q1 2024 after selling out during the quarter.
  • Loomis, Sayles & Company sold 661 Maravai LifeSciences shares in Q1 2024, an estimated $4K.
  • Loomis, Sayles & Company first reported a position in Maravai LifeSciences in Q3 2021 and held it in 8 quarters.
  • Loomis, Sayles & Company's Maravai LifeSciences position peaked at $23K in Q1 2023.
  • 210 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2024.

Based on Loomis, Sayles & Company's 13F filing for Q1 2024, filed 14 May 2024.